Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (61-70 of 436) with videos related to

Pageof 44
Sort By:
The New England Journal of Medicine|September 15, 2020
Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine ApprovalJerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|October 22, 2015
The 21st Century Cures ActAaron S Kesselheim, Jerry Avorn
The New England Journal of Medicine|June 4, 2015
The 21st Century Cures Act--Will It Take Us Back in Time?Jerry Avorn, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|June 5, 2009
Using patent data to assess the value of pharmaceutical innovationAaron S Kesselheim, Jerry Avorn
The Journal of Rheumatology|January 1, 2003
Do gastroprotective drugs prevent NSAID toxicity?Daniel H Solomon, Jerry Avorn
Current Opinion in Rheumatology|February 25, 2003
Pharmacoepidemiology and rheumatic diseases: 2001-2002Daniel H Solomon, Jerry Avorn
Nature Medicine|October 13, 2011
The NIH translational research center might trade public risk for private rewardJerry Avorn, Aaron S Kesselheim
Annals of Internal Medicine|June 9, 2005
Over-the-counter statinsNiteesh K Choudhry, Jerry Avorn
The Virtual Mentor : VM|December 13, 2012
Educating Trainees about the Cost of MedicationsMichael A Fischer, Jerry Avorn
BMJ (Clinical Research Ed.)|December 21, 2013
New and unproved medical devicesAaron S Kesselheim, Jerry Avorn
Pageof 44

Showing results (61-70 of 436) with videos related to

Sort By:
Pageof 44
The New England Journal of Medicine|September 15, 2020
Up Is Down - Pharmaceutical Industry Caution vs. Federal Acceleration of Covid-19 Vaccine ApprovalJerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|October 22, 2015
The 21st Century Cures ActAaron S Kesselheim, Jerry Avorn
The New England Journal of Medicine|June 4, 2015
The 21st Century Cures Act--Will It Take Us Back in Time?Jerry Avorn, Aaron S Kesselheim
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|June 5, 2009
Using patent data to assess the value of pharmaceutical innovationAaron S Kesselheim, Jerry Avorn
The Journal of Rheumatology|January 1, 2003
Do gastroprotective drugs prevent NSAID toxicity?Daniel H Solomon, Jerry Avorn
Current Opinion in Rheumatology|February 25, 2003
Pharmacoepidemiology and rheumatic diseases: 2001-2002Daniel H Solomon, Jerry Avorn
Nature Medicine|October 13, 2011
The NIH translational research center might trade public risk for private rewardJerry Avorn, Aaron S Kesselheim
Annals of Internal Medicine|June 9, 2005
Over-the-counter statinsNiteesh K Choudhry, Jerry Avorn
The Virtual Mentor : VM|December 13, 2012
Educating Trainees about the Cost of MedicationsMichael A Fischer, Jerry Avorn
BMJ (Clinical Research Ed.)|December 21, 2013
New and unproved medical devicesAaron S Kesselheim, Jerry Avorn
Pageof 44